<DOC>
	<DOCNO>NCT00005069</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient metastatic kidney cancer .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Metastatic Kidney Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate efficacy arsenic trioxide patient metastatic renal cell cancer . II . Determine safety regimen patient population . OUTLINE : Patients receive arsenic trioxide IV 1-4 hour daily 5 day . Treatment continue every 4 week maximum 12 course absence disease progression unacceptable toxicity . Patients follow least 1 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 6-19 month .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic renal cell cancer Bidimensionally measurable disease No brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : Karnofsky 70100 % Life expectancy : Greater 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal ALT AST great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN ( great 1.95 mg/dL MSKCC ) Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 month study No prior malignancy unless curatively treated disease free past 5 year consider low risk recurrence PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy recover No concurrent biologic therapy Chemotherapy : At least 4 week since prior cytotoxic chemotherapy recover No concurrent cytotoxic chemotherapy Endocrine therapy : At least 4 week since prior hormonal therapy recover No concurrent hormonal therapy Radiotherapy : At least 4 week since prior radiotherapy No concurrent radiotherapy Surgery : At least 4 week since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent renal cell cancer</keyword>
</DOC>